Kemimedi

KemiMedi is a South Korean biotechnology company dedicated to the discovery and development of novel therapeutic agents for a range of medical conditions, including urological disorders, oncology, and inflammatory diseases. The company's research strategy integrates traditional medicinal knowledge with modern drug discovery technologies to produce high-quality clinical candidates. KemiMedi's lead program, KH-101, is being developed for the treatment of benign prostatic hyperplasia and has progressed into mid-stage clinical trials. Additionally, the company is advancing a pipeline of small molecule and natural product-based therapies targeting atopic dermatitis and various cancers. KemiMedi is publicly traded on the KONEX market in South Korea and continues to seek strategic partnerships to expand its global reach.